Skip to content

MDMA: all studies

Page 43 of 345: studies 421 to 430 of 3,446, newest first. Back to the MDMA overview

Research

MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder

Frontiers in Psychiatry November 3, 2022 Devon Christie, Berra Yazar-Klosinski, Ekaterina Nosova et al. 8 citations

IntroductionIncreasing evidence demonstrates 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) may be a safe and effective treatment for post-traumatic stress disorder (PTSD). There is growing interest in MDMA-AT to address a range of other health challenges. Chronic pain and PTSD are frequently comorbid, reciprocally interdependent conditions, though the possible role of...

Therapeutic setting as an essential component of psychedelic research methodology: Reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder

Frontiers in Psychiatry November 3, 2022 Lauren Okano, Bri Deyo, Alida Brandenburg et al. 24 citations

Research of psychedelic assisted therapies is at an all-time high, though few studies highlight extra-pharmacological factors that may affect treatment efficacy. One critical set of attributes includes the therapeutic setting itself, which describe the physical and socio-cultural environments in which the drug-assisted session occurs. Despite enduring consensus of the influence of setting,...

DOI: 10.3389/fpsyt.2022.965641 (opens in new tab) Traumatic stress Psychotherapist Clinical trial Clinical psychology

Assessing the quality of publicly available videos on MDMA‐assisted psychotherapy for PTSD

American Journal on Addictions November 1, 2022 Mariam Kyarunts, Meghna P. Mansukhani, Larissa L. Loukianova et al. 26 citations

AbstractBackground and ObjectivesPatients increasingly rely on the Internet for healthcare information. This study aimed to evaluate the quality of videos on 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy for posttraumatic stress disorder (PTSD) on YouTube™.MethodsYouTube™ was searched for the terms “MDMA” and “PTSD.” The 100 most viewed videos were analyzed using three...

Cardiac effects of ephedrine, norephedrine, mescaline, and 3,4-methylenedioxymethamphetamine (MDMA) in mouse and human atrial preparations

Naunyn-Schmiedeberg's Archives of Pharmacology November 1, 2022 Joachim Neumann, Karyna Azatsian, Christian Höhm et al. 7 citations

Abstract The use of recreational drugs like ephedrine, norephedrine, 3,4-methylenedioxymethamphetamine (MDMA), and mescaline can lead to intoxication and, at worst, to death. One reason for a fatal course of intoxication with these drugs might lie in cardiac arrhythmias. To the best of our knowledge, their inotropic effects have not yet been studied in isolated human cardiac preparations....

Ignatius Loyola and Konstantin Stanislavsky in the interpretation of Sergey Eisenstein: from mystical ecstasy to editing

St. Tikhons' University Review October 31, 2022 Tinatin Do Egito

The article examines the point of Soviet art's 1920-1930 influence on secular processes in society. The model of the psychology of art proposed by L. Vygotsky, based on Marxist dogmatics, becomes the starting point for the search of creative elite, particularly, for the film director and art theorist Sergei Eisenstein. They are brought together by a common understanding of art as a sign system...

Demographic and health characteristics of 3,4-methylenedioxymethamphetamine users (MDMA, ecstasy).

Psychiatria Polska October 31, 2022 Gniewko Więckiewicz, Dariusz Danel, Magdalena Piegza et al. 2 citations

MDMA is one of the most commonly used drugs in the world. Clinical studies are currently being conducted around the world on the use of this substance in the treatment of PTSD and alcoholism. However, little demographic information is available on users who use the substance for recreational purposes. The aim was to determine basic demographic and helath characteristics with validated tools....

Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes

Journal of Psychopharmacology October 31, 2022 Grant Jones 28 citations

Background: Psychedelics are receiving renewed attention within Western medicine as they represent potential treatments for many difficult-to-treat mental health disorders. However, psychedelic science is limited in its focus and inclusion of racial and ethnic minorities. Hence, this study examines whether race and ethnicity moderate the associations that naturalistic...

Ecstasy

October 27, 2022 Peder Clark

First patented by Merck in the early twentieth century, and reinvented by American chemists in the 1960s and 1970s, MDMA (3,4-methylenedioxymethamphetamine) has been characterised as a good-time party drug with a dark side. Ecstasy, ‘E’, ‘X’ or ‘molly’ is connected in contemporary parlance with EDM mega-raves and the sometimes lethal consequences of over-consumption. This chapter suggests that...

Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”

Frontiers in Psychiatry October 26, 2022 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al. 11 citations

Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the...

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy

Frontiers in Psychiatry October 12, 2022 Robert J Sottile, Thomas Vida 30 citations

Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive nightmares, an assortment of somatic symptoms, associations with severe long-term health problems, and an elevated risk of suicide, as much as 40–70% of patients suffer from refractory disease....